Plasma Exchange in Alzheimer's.

AMBAR (Alzheimer Management by Albumin Replacement) is a Phase IIb/III randomized, sham-placebo-controlled, multicenter clinical trial — 41 centers in Spain and the United States — sponsored by Grifols.

It enrolled 496 patients with mild-to-moderate Alzheimer's disease and evaluated therapeutic plasma exchange with human albumin replacement (4–5%) vs. sham placebo over 14 months. It is the largest-scale controlled trial published to date evaluating this strategy in neurodegeneration.

In the full intention-to-treat population, AMBAR showed favorable trends without reaching statistical significance on the combined co-primary endpoint (ADAS-Cog + ADCS-ADL).

In the pre-specified subgroup analysis, patients with moderate Alzheimer's at baseline showed a 61% slowing of functional decline measured by ADCS-ADL vs. placebo (p<0.05), along with improvements on secondary scales of quality of life and behavior.

The honest interpretation: AMBAR did not demonstrate general efficacy in mild Alzheimer's, but generated a clinically relevant signal in the moderate subgroup that justifies further investigation.

The mechanism rests on three simultaneous axes:

· Peripheral sink hypothesis (DeMattos et al., PNAS 2001): reducing plasma amyloid-β induces a gradient that draws Aβ from the central nervous system to the periphery, where it is cleared.
· Albumin replacement: aged, oxidized, Aβ-saturated albumin is replaced with fresh human albumin with preserved binding capacity.
· Inflammaging modulation: reduction of circulating pro-inflammatory cytokines (TNF-α, IL-6) that keep cerebral microglia activated.

Plasma exchange acts on peripheral circulation, not directly on the brain.

It is the hypothesis posited by DeMattos et al. (PNAS 2001) that cerebral amyloid-β is in dynamic equilibrium with plasma amyloid-β across the blood-brain barrier.

By sustainably reducing plasma Aβ concentration, a gradient is established that favors net efflux of Aβ from the brain to the periphery, where it is cleared.

This hypothesis is the shared mechanistic basis not only of plasma exchange with albumin, but also of most anti-amyloid monoclonal antibodies (lecanemab, donanemab) — all of them act peripherally, not directly on brain parenchyma.

No. Therapeutic plasma exchange with albumin replacement does not have regulatory approval from INVIMA (Colombia) or the FDA (United States) as specific treatment for Alzheimer's disease.

TPE is approved in Colombia for specific hematologic, immune-mediated neurologic (Guillain-Barré, myasthenia gravis, CIDP), and nephrologic indications.

AMBAR established a clinically relevant signal in a subgroup, but did not result in regulatory approval. Any discussion of TPE in patients with neurodegeneration is educational and research-oriented — not approved therapy — and must occur case by case under strict medical criteria.

AMBAR uses therapeutic plasma exchange with human albumin replacement — an apheresis intervention. Monoclonals (lecanemab, donanemab, FDA-approved 2023–2024) are intravenously infused antibodies that bind specifically to amyloid-β oligomers or protofibrils.

They share the conceptual peripheral-sink mechanism, but AMBAR acts on multiple pathways simultaneously (Aβ + inflammaging + oxidative stress + aged albumin), whereas monoclonals act on a single molecular target.

Monoclonals have regulatory approval; AMBAR did not. Safety profiles also differ: monoclonals carry a documented risk of ARIA (amyloid-related imaging abnormalities — microhemorrhages and cerebral edema), while TPE does not present this effect.

Beyond AMBAR, there are three converging lines:

· Parabiosis (Villeda et al., Nature Medicine 2014): young plasma reverses age-related cognitive and synaptic deficits in mice.
· Young plasma in humans (Sha SJ et al., Alkahest PLASMA trial, JAMA Neurology 2019): evaluated in mild-to-moderate Alzheimer's with safety but limited efficacy results.
· Buck Institute (Fuentealba et al., Aging Cell 2025): 2.6-year reduction in biological age with TPE + IVIG, with changes in inflammaging biomarkers that are known drivers of neurodegeneration.

It is an active research field with growing biological plausibility — but still without an approved treatment derived from it.

Wellness Care does not offer Alzheimer's treatment. Therapeutic plasma exchange does not have regulatory approval as treatment for this condition.

What we do: evaluate patients with cognitive concern, subjective mild cognitive impairment, or risk factors for neurodegeneration via advanced biomarker panels — inflammaging, neuro-specific markers, cerebral metabolic profile — and design individualized longevity medicine protocols.

These protocols may or may not include TPE depending on the case, biomarker profile, and available evidence for that specific profile. The decision is always medical and individualized, never a menu.